{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:52:55Z","timestamp":1789908775556,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T00:00:00Z","timestamp":1526083200000},"content-version":"am","delay-in-days":406,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI095611"],"award-info":[{"award-number":["U01AI095611"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI106754"],"award-info":[{"award-number":["U19AI106754"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI089987"],"award-info":[{"award-number":["U19AI089987"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI118610"],"award-info":[{"award-number":["U19AI118610"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI127658"],"award-info":[{"award-number":["R01AI127658"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201300023C"],"award-info":[{"award-number":["HHSN272201300023C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI124297"],"award-info":[{"award-number":["U01AI124297"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI117873"],"award-info":[{"award-number":["U19AI117873"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI097092"],"award-info":[{"award-number":["P01AI097092"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.coviro.2017.04.005","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T15:15:50Z","timestamp":1494602150000},"page":"102-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Inactivated influenza virus vaccines: the future of TIV and QIV"],"prefix":"10.1016","volume":"23","author":[{"given":"Michael","family":"Schotsaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2017.04.005_bib0005","doi-asserted-by":"crossref","first-page":"e0147271","DOI":"10.1371\/journal.pone.0147271","article-title":"Infection in health personnel with high and low levels of exposure in a hospital setting during the H1N1 2009 influenza A pandemic","volume":"11","author":"Sandoval","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2017.04.005_bib0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4161\/hv.8.1.17623","article-title":"The rationale for quadrivalent influenza vaccines","volume":"8","author":"Ambrose","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.coviro.2017.04.005_bib0015","first-page":"203","article-title":"Cold-adapted influenza viruses for use as live vaccines for man","volume":"14","author":"Maassab","year":"1990","journal-title":"Adv. Biotechnol. Processes"},{"key":"10.1016\/j.coviro.2017.04.005_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-3083.2005.01633.x","article-title":"Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB\/c mice","volume":"62","author":"Hovden","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/jcm.24.1.157-160.1986","article-title":"Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus","volume":"24","author":"Clements","year":"1986","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0030","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_bib0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1750-2659.2010.00183.x","article-title":"The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults","volume":"5","author":"Ambrose","year":"2011","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.coviro.2017.04.005_bib0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14760584.2017.1240041","article-title":"M2-based influenza vaccines: recent advances and clinical potential","volume":"16","author":"Kolpe","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.coviro.2017.04.005_bib0045","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: shifting to better vaccines","volume":"34","author":"Berlanda Scorza","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.005_bib0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","article-title":"Influenza virus hemagglutinin stalk-based antibodies and vaccines","volume":"3","author":"Krammer","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coviro.2016.02.002","article-title":"Novel universal influenza virus vaccine approaches","volume":"17","author":"Krammer","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0060","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.4049\/jimmunol.1003057","article-title":"Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus","volume":"186","author":"LaMere","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0065","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.coviro.2017.04.005_bib0070","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.coviro.2017.04.005_sbref0075","doi-asserted-by":"crossref","first-page":"e02556","DOI":"10.1128\/mBio.02556-14","article-title":"Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice","volume":"6","author":"Wohlbold","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2017.04.005_sbref0080","first-page":"818","article-title":"Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein","volume":"215","author":"Jegaskanda","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_bib0085","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/infdis\/jiw262","article-title":"Generation and protective ability of influenza virus-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental challenge","volume":"214","author":"Jegaskanda","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_bib0090","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.4049\/jimmunol.1201574","article-title":"Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies","volume":"190","author":"Jegaskanda","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0095","doi-asserted-by":"crossref","first-page":"E5944","DOI":"10.1073\/pnas.1613225113","article-title":"Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact","volume":"113","author":"Leon","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.04.005_bib0100","doi-asserted-by":"crossref","first-page":"e02500","DOI":"10.1128\/JVI.02500-16","article-title":"Hierarchical and redundant roles of activating FcgammaRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies","volume":"91","author":"Van den Hoecke","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0105","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.0902147","article-title":"Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection","volume":"186","author":"El Bakkouri","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0110","doi-asserted-by":"crossref","first-page":"20365","DOI":"10.1073\/pnas.0911580106","article-title":"Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population","volume":"106","author":"Greenbaum","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.04.005_bib0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.coviro.2017.04.005_bib0120","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.coviro.2017.04.005_bib0125","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1086\/657311","article-title":"Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong","volume":"51","author":"Cowling","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_sbref0130","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/infdis\/jiu654","article-title":"Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children","volume":"211","author":"Mohn","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_bib0135","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00414-16","article-title":"Comparisons of the humoral and cellular immune responses induced by live attenuated influenza vaccine and inactivated influenza vaccine in adults","volume":"24","author":"Hoft","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.coviro.2017.04.005_sbref0140","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/infdis\/jiu190","article-title":"Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines","volume":"210","author":"Sasaki","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_bib0145","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.vaccine.2015.12.023","article-title":"Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets","volume":"34","author":"Music","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.005_bib0150","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1073\/pnas.1012199108","article-title":"Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus","volume":"108","author":"Song","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.04.005_bib0155","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/irv.12142","article-title":"Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration","volume":"7","author":"Budimir","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.coviro.2017.04.005_bib0160","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/iai.8.1.130-131.1973","article-title":"Effect of influenza anti-neuraminidase antibody on virus neutralization","volume":"8","author":"Kasel","year":"1973","journal-title":"Infect. Immun."},{"key":"10.1016\/j.coviro.2017.04.005_bib0165","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase","volume":"207","author":"Couch","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_bib0170","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1172\/JCI41902","article-title":"Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine","volume":"120","author":"Corti","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.coviro.2017.04.005_bib0175","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fimmu.2012.00087","article-title":"Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem","volume":"3","author":"Thomson","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0180","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1073\/pnas.1414070111","article-title":"Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans","volume":"111","author":"Ellebedy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.04.005_sbref0185","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/npjvaccines.2016.15","article-title":"A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice","volume":"1","author":"Nachbagauer","year":"2016","journal-title":"npj Vaccines"},{"key":"10.1016\/j.coviro.2017.04.005_bib0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 adjuvant: the best insurance against influenza strain diversity","volume":"10","author":"O\u2019Hagan","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.coviro.2017.04.005_bib0195","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/CVI.00480-10","article-title":"Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A\/H1N1\/2009 influenza virus vaccine administered to adults during two randomized controlled trials","volume":"18","author":"Roman","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0200","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1038\/srep37229","article-title":"Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination","volume":"6","author":"Galson","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.coviro.2017.04.005_bib0205","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/infdis\/jiu284","article-title":"Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study","volume":"210","author":"Roy-Ghanta","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_bib0210","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.coviro.2017.04.005_sbref0215","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.1038\/ncomms7833","article-title":"Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.coviro.2017.04.005_bib0220","doi-asserted-by":"crossref","first-page":"26494","DOI":"10.1038\/srep26494","article-title":"ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination","volume":"6","author":"Bentebibel","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.coviro.2017.04.005_bib0225","doi-asserted-by":"crossref","first-page":"176ra132","DOI":"10.1126\/scitranslmed.3005191","article-title":"Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination","volume":"5","author":"Bentebibel","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.coviro.2017.04.005_bib0230","first-page":"740","article-title":"Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination","volume":"215","author":"Trieu","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.005_bib0235","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aag2045","article-title":"ZBP1\/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways","volume":"1","author":"Kuriakose","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.coviro.2017.04.005_bib0240","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.chom.2016.09.014","article-title":"DAI senses influenza A virus genomic RNA and activates RIPK3-dependent cell death","volume":"20","author":"Thapa","year":"2016","journal-title":"Cell Host Microbe"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187962571630150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187962571630150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:59:29Z","timestamp":1761818369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187962571630150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":48,"alternative-id":["S187962571630150X"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2017.04.005","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inactivated influenza virus vaccines: the future of TIV and QIV","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2017.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}